-
SAMHSA/CSAT. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. 2004. PMID: 22514846.
-
SAMHSA. Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update. Winter 2016.
-
FSMB. Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office. FSMB Website. 2013.
-
ASAM. 2020 National Practice Guideline. Am Soc Addict Med. 2020.
-
Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: A Rapid Review. J Gen Intern Med. December 2020;35(Suppl 3):954-963. doi:10.1007/s11606-020-06257-4. PMCID: PMC7728943. PMID: 33145687.
-
Trescot A, Datta S, Lee M, Hansen H. Opioid Pharmacology. Pain Physician. 2008;11(2 Suppl):S133-153.
-
Williams J. Basic Opioid Pharmacology. Rev Pain. March 2008;1(2):2-5. doi:10.1177/204946370800100202. PMCID: PMC4589929. PMID: 26524987.
-
Pathan H, Williams J. Basic Opioid Pharmacology: An Update. Br J Pain. February 2012;6(1):11-16. doi:10.1177/2049463712438493. PMCID: PMC4590096. PMID: 26516461.
-
Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. In: Vol Publication No. PEP20-02-01-006. Treatment Improvement Protocol (TIP). Rockville, MD: SAMHSA; 2020.
-
Richardson MG, Raymond BL. Lack of Evidence for Ceiling Effect for Buprenorphine Analgesia in Humans. Anesth Analg. July 2018;127(1):310-311. doi:10.1213/ANE.0000000000003368. PMID: 29624528.
-
Paulozzi L, Baldwin G. CDC Grand Rounds: Prescription Drug Overdoses — a U.S. Epidemic. CDC Morb Mortal Wkly Rep. 2012;61(01):10-13.
-
Rudd RA. Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65. doi:10.15585/mmwr.mm655051e1.
-
Dunn K, Saunders K, Rutter C, et al. Opioid Prescriptions for Chronic Pain and Overdose: A Cohort Study. Ann Intern Med. 2010;152(2):85-92. PMCID: PMC3000551. PMID: 20083827.
-
American Psychiatric Association. Substance-Related and Addictive Disorders. APA. 2013.
-
Kosten T, George T. The Neurobiology of Opioid Addiction: Implications for Treatment. NIDA Sci Pract Perspect. 2002;1(1):13-20. PMCID: PMC2851054. PMID: 18567959.
-
Henry J. Metabolic Consequences of Drug Misuse. Br J Anaesth. 2000;85(1):136-142. PMID: 10928002.
-
Volkow N. NIDA-supported science leads to first FDA-approved medication for opioid withdrawal. NIDA. 2018.
-
FDA. FDA approves the first non-opioid treatment for management of opioid withdrawal symptoms in adults. 2018.
-
National Drug Intelligence Center (NDIC). Intelligence Bulletin: Buprenorphine: Potential for Abuse. 2004.
-
SAMHSA. Protracted withdrawal. SAMHSA Advis. 2010;9(1).
-
Oreskovich M, Saxon A, Ellis M, et al. A Double-Blind, Double-Dummy, Randomized, Prospective Pilot Study of the Partial Mu Opiate Agonist, Buprenorphine, for Acute Detoxification from Heroin. Drug Alcohol Depend. 2005;77(1):71-79. PMID: 15607843.
-
Amass L, Ling W, Freese T, et al. Bringing Buprenorphine-Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience. Am J Addict. 2004;13:Suppl 1: S42-66. PMCID: PMC1255908. PMID: 15204675.
-
Kakko J, Svanborg K, Kreek M, et al. 1-Year Retention and Social Function after Buprenorphine-Assisted Relapse Prevention Treatment for Heroin Dependence in Sweden: A Randomised, Placebo-Controlled Trial. Lancet. 2003;361(9358):662-668. PMID: 12606177.
-
21 USC § 812. Schedules of controlled substances. 2012.
-
Johnson R, Strain E, Amass L. Buprenorphine: How to Use It Right. Drug Alcohol Depend. 2003;70(suppl 2):S59-S77. PMID: 12738351.
-
Mendelson J, Jones R. Clinical and Pharmacological Evaluation of Buprenorphine and Naloxone Combinations: Why the 4:1 Ratio for Treatment?. Drug Alcohol Depend. 2003;70(2S):S29-S37. PMID: 12738348.
-
Walsh S. Clinically Relevant Pharmacology of Buprenorphine. 2009.
-
Kahan M, Srivastava A, Ordean A, et al. Buprenorphine: New Treatment of Opioid Addiction in Primary Care. Can Fam Physician. 2011;57(3):281-289. PMCID: PMC3056674. PMID: 21402963.
-
Renner J, Saxon A, Levounis P. Buprenorphine Update and Evolving Standards of Care. IPS: The Mental Health Services Conference. October 2015. New York City.
-
Kissin W, McLeod C, Sonnefeld J, et al. Experiences of a National Sample of Qualified Addiction Specialists Who Have and Have Not Prescribed Buprenorphine for Opioid Dependence. J Addict Dis. 2006;25(4):91-103. PMID: 17088229.
-
Alford D, Labelle C, Kretsch N, et al. Collaborative Care of Opioid-Addicted Patients in Primary Care Using Buprenorphine: Five-Year Experience. Arch Intern Med. 2011;171(5):425-431.
-
Arfken C, Johanson C, di Menza S, et al. Expanding Treatment Capacity for Opioid Dependence with Office-Based Treatment with Buprenorphine: National Surveys of Physicians. J Subst Abuse Treat. 2010;39(2):96-104. PMID: 20598829.
-
Mintzer I, Eisenberg M, Terra M, et al. Treating Opioid Addiction with Buprenorphine-Naloxone in Community-Based Primary Care Settings. Ann Fam Med. 2007;5(2):146-150. PMCID: PMC1838690. PMID: 17389539.
-
FDA. FDA approves first buprenorphine implant for treatment of opioid dependence. FDA News Events. May 26, 2016.
-
FDA. FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder. November 30, 2017.
-
Labelle C, Han S, Bergeron A, et al. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers. J Subst Abuse Treat. 2015;15. PMCID: PMC4682362. PMID: 26233698.
-
FDA. Medication Guide: ButransTM CIII (buprenorphine) Transdermal System. 2010.
-
Kraus M, Alford D, Kotz M, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction. J Addict Med. 2011;5(4):254-263.
-
FDA. Bunavail prescribing information. 2014.
-
Stanton A, McLoed C, Luckey B, et al. SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program. 37th Annual Medical- Scientific Conference of the American Society of Addiction Medicine. 2006.
-
Dahan A, Yassen A, Romberg R, et al. Buprenorphine Induces Ceiling in Respiratory Depression but Not in Analgesia. Br J Anaesth. 2006;96(5):627-632. PMID: 16547090.
-
Huestis M. High-dose buprenorphine in humans. In: In: Kintz P, Marquet P, Eds. Buprenorphine Therapy of Opiate Addiction. Vol Totowa, NJ: Humana Press, Inc; 2002.
-
Chiang C, Hawks R. Pharmacokinetics of the Combination Tablet of Buprenorphine and Naloxone. Drug Alcohol Depend. 2003;70(suppl 2):S39-S47. PMID: 12738349.
-
Tzschentke TM. Behavioral Pharmacology of Buprenorphine, with a Focus on Preclinical Models of Reward and Addiction. Psychopharmacology (Berl). April 2002;161(1):1-16. doi:10.1007/s00213-002-1003-8. PMID: 11967625.
-
Donaher P, Welsh C. Managing Opioid Addiction with Buprenorphine. Am Fam Physician. 2006;73(9):1573-1578.
-
SAMHSA. Substance Use Disorders. SAMHSA Website. 2014.
-
Yokell M, Zaller N, Green T, et al. Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review. Curr Drug Abuse Rev. 2011;4:28-41. PMCID: PMC3154701. PMID: 21466501.
-
Nasser A, Heidbreder C, Liu Y, et al. Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers. Clin Pharmacokinet. 2015;54(8):837-849. PMID: 25603822.
-
Reckitt Benckiser Pharmaceuticals Inc. Suboxone Prescribing Information. 2014.
-
Farney R, McDonald A, Boyle K, et al. Sleep Disordered Breathing in Patients Receiving Therapy with Buprenorphine/Naloxone. Eur Respir. 2013;42:394-403. PMID: 23100497.
-
Lintzeris N, Clark N, Muhleisen P, et al. National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Heroin Dependence. 2001.
-
Weiss R, Potter J, Fiellin D. Adjunctive Counseling During Brief and Extended Buprenorphine-Naloxone Treatment for Prescription Opioid Dependence. Arch Gen Psychiatry. 2012;68(12):1238-1246. PMCID: PMC3470422. PMID: 22065255.
-
Fiellin D, Schottenfeld R, Cutter C, et al. Primary Care-Based Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid Dependence: A Randomized Clinical Trial. JAMA Intern Med. 2014;174(12):1947-1954.
-
Dunn K, Sigmon S, Strain E. The Association between Outpatient Buprenorphine Detoxification Duration and Clinical Treatment Outcomes: A Review. Drug Alcohol Depend. 2011;119(1-2):1-9. PMCID: PMC3205338. PMID: 21741781.
-
Kao M-C, Zheng P, Mackey S, et al. Trends in Benzodiazepine Prescription and Co-Prescription with Opioids in the United States, 2002––2009. AAPM Annual Meeting. July 2014.
-
Maxwell J, McCance-Katz E. Indicators of Buprenorphine and Methadone Use and Abuse: What Do We Know?. Am J Addict. 2010;19(1):73-88. PMCID: PMC3723402. PMID: 20132124.
-
ASAM. The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use. June 1, 2015.
-
Stein D, Isper J, Seedat S. Pharmacotherapy for Post Traumatic Stress Disorder (PTSD). Cochrane Database Syst Rev. 2006;1:CD002795. PMCID: PMC6993948. PMID: 16437445.
-
Taylor F, Martin P, Thompson C, et al. Prazosin Effects on Objective Sleep Measures and Clinical Symptoms in Civilian Trauma Posttraumatic Stress Disorder: A Placebo-Controlled Study. Biol Psychiatry. 2008;63(6):629-632. PMCID: PMC2350188. PMID: 17868655.
-
Drugs.com. Doxazosin. Drugs.com. January 6, 2000.
-
McNicholas L. Buprenorphine: Induction, Dosing and Related Issues. American Psychiatric Association Sponsored Webinar; 2011.
-
Food and Drug Administration (FDA). Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategy (REMS). Initial REMS / , updated 6/2015 2013.
-
NIAAA. Alcohol Facts and Statistics. NIAAA. 2018.
-
Saber-Tehrani A, Bruce R, Altice F. Pharmacokinetic Drug Interactions and Adverse Consequences between Psychotropic Medications and Pharmacotherapy for the Treatment of Opioid Dependence. Am J Drug Alcohol Abuse. 2011;37(1):1-11. PMID: 21247284.
-
Guo A, Ma J, Best B, et al. Urine Specimen Detection of Concurrent Nonprescribed Medicinal and Illicit Drug Use in Patients Prescribed Buprenorphine. J Anal Toxicol. 2013;37(9):636-641. PMID: 24080973.
-
NIH. National Trends. 2014.
-
APA. Focus on Marijuana: Current Risks and Controversies. Am Psychiatr Assoc Webinar. 2012.
-
Gruber V, McCance-Katz E. Methadone, Buprenorphine, and Street Drug Interactions with Antiretroviral Medications. Curr HIV/AIDS Rep. 2010;7(3):156-160. PMCID: PMC2892618. PMID: 20532839.
-
McCance-Katz E, Moody D, Morse G, et al. Interaction between Buprenorphine and Atazanavir or Atazanavir/Ritonavir. Drug Alcohol Depend. 2007;91(2-3):269-278. PMCID: PMC3272856. PMID: 17643869.
-
McCance-Katz E. Treatment of Opioid Dependence and Coinfection with HIV and Hepatitis C Virus in Opioid-Dependent Patients: The Importance of Drug Interactions between Opioids and Antiretroviral Agents. Clin Infect Dis. 2005;41(suppl 1):S89-95. PMID: 16265622.
-
Saxon A, Ling W, Hillhouse M, et al. Buprenorphine/Naloxone and Methadone Effects on Laboratory Indices of Liver Health: A Randomized Trial. Drug Alcohol Depend. 2013;128:71-76. PMCID: PMC3543467. PMID: 22921476.
-
Herve S, Riachi G, Noblet C, et al. Acute Hepatitis Due to Buprenorphine Administration. Eur J Gastroenterol Hepatol. 2004;16(10):1033-1037. PMID: 15371928.
-
Durand F, Valla D. Assessment of Prognosis of Cirrhosis. Clin Pharmacokinet. 2008;28(1):110-122. PMID: 18293281.
-
DailyMed. Buprenorphine and Naloxone- buprenorphine hydrochloride and naloxone hydrochloride tablet. DailyMed US Natl Libr Med. December 6, 2016.
-
ASAM. Summary of the Comprehensive Addiction and Recovery Act. 2016.
-
SAMHSA. Methadone. SAMHSA.gov. 2020.
-
Mattick R, Breen C, Kimber J. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Libr. 2014.
-
Borg L, Kreek M. The pharmacology of opioids. In: In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine. Vol 3. 3rd ed. Chevy Chase, Md: American Society of Addiction Medicine; 2003.
-
Lee J, Friedmann P, Kinlock T, et al. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med. 2016;374:1232-1242.
-
PCSS. Vivitrol: How important is this piece of the treatment puzzle?. 2015.
-
PCSS. XR-Naltrexone: A step-by-step guide. 2017.
-
Substance Abuse and Mental Health Services Administration (US), Office of the Surgeon General (US). Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health. Washington (DC): US Department of Health and Human Services; 2016. PMID: 28252892.
-
SAMHSA. Decisions in Recovery. Treatment for Opioid Use Disorder.. 2017.
-
Fudin J. A Brief Review of Buprenorphine Products. March 22, 2016.
-
Breen C. There’s a New Buprenorphine on the Block | Dr. Jeffrey Fudin. PainDr. February 12, 2018.
-
Strain E, Moody D, Stoller K, et al. Relative Bioavailability of Different Buprenorphine Formulations under Chronic Dosing Conditions. Drug Alcohol Depend. 2004;74(1):37-43. PMID: 15072805.
-
Ling W, Casadonte P, Bigelow G. Buprenorphine Implants for Treatment of Opioid Dependence. JAMA. 2010;304(14):1576-1583. PMID: 20940383.
-
Larance B, Lintzeris N, Dietze P, et al. The Diversion and Injection of a Buprenorphine-Naloxone Soluble Film Formulation. Drug Alcohol Depend. 2014;136:21-27.
-
Rx List. Suboxone. Rx List Website. July 14, 2020.
-
Sontag D. Addiction Treatment With a Dark Side. N Y Times. 2013.
-
Orexo US Inc. Zubsolv prescribing information. October 2019.
-
ASAM. The ASAM National Practice Guideline For the Treatment of Opioid Use Disorder 2020 Focused Update. 2020.
-
Dart R. Evaluation of ADFs Using RADARS System Data. 2011.
-
Alho H, Sinclair D, Vuori E, et al. Abuse Liability of Buprenorphine-Naloxone Tablets in Untreated IV Drug Users. Drug Alcohol Depend. 2007;88(1):75-78. PMID: 17055191.
-
Chen M, Beebe K. A randomized trial of Probuphine implants in adults stabilized on sublingual buprenorphine. American Society of Addiction Medicine (ASAM) Annual Meeting. 2016.
-
Rosenthal R, Lofwall M, Kim S, et al. Effect of Buprenorphine Implants on Illicit Opioid Use among Abstinent Adults with Opioid Dependence Treated with Sublingual Buprenorphine. A Randomized Clinical Trial. JAMA. 2016;316:282-290.
-
Sublocade. Medication Guide Sublocade (buprenorphine extended-release) injection, for subcutaneous use (CIII). November 2017.
-
Medscape. Sublocade (buprenorphine, long-acting injection) dosing, indications, interactions, adverse effects, and more. 2018.
-
American Society of Health-System Pharmacists. Buprenorphine Injection: MedlinePlus Drug Information. April 15, 2018.
-
Reckitt Benckiser Pharmaceuticals Inc. Buprenex injectable – RX only – Schedule III. 2007.
-
Belbuca. Belbuca HPC important safety information. www.belbuca.com. 2015.
-
Purdue Pharma. Butrans – buprenorphine patch, extended release. 2019.
-
Sullivan M, Gordon A. MAT training: Provider’s clinical support system for medication assisted treatment. 2013.
